[Rare tumors: Angiosarcoma].

Abstract

Angiosarcomas are a rare subtype representing 1-2% of soft tissue sarcomas. Risk factors are rarely elucidated but radiotherapy and lymphedema are the most common ones, usually following local treatment for local breast cancer. Despite the improvement of our knowledge, the prognosis remains poor with 35-40% of 5 year-overall survival. Local treatment when feasible should include a R0 surgery completed with adjuvant radiation. When metastatic, front lines chemotherapies include doxorubicine or weekly paclitaxel. If possible, in oligometastatic patients, metastasectomy should always be considered allowing the best responses. The knowledge of angiosarcoma's biology is rapidly increasing and new biomarkers are emerging. The use of immunotherapy in particular subtypes including head and neck angiosarcomas shows promising results. The model of the angiosarcoma project, a patient-participating study, seems to be an excellent way to study rare tumors. We should focus our efforts on understanding the underlying molecular biology to propose the best precision medicine for those patients.

• Authors: Nathan El-Ghazzi, Jacques-Olivier Bay
• Journal: Bulletin du cancer (Bull Cancer) Vol. 110 Issue 5 Pg. 581-588 (May 2023) ISSN: 1769-6917 [Electronic] France
• Vernacular Title: Tumeurs rares : angiosarcome.
• PMID: 36973135 (Publication Type: English Abstract, Journal Article)
• Copyright: Copyright © 2023 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.

Chemical References

• Paclitaxel

Topics

• Humans
• Female
• Hemangiosarcoma (pathology, surgery)
• Sarcoma (pathology)
• Paclitaxel (therapeutic use)
• Prognosis
• Breast Neoplasms (drug therapy)